<?xml version="1.0" encoding="UTF-8"?>
<eudamedExport entity="devices">
  <row>
    <udiDi>04251778106661</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Reloxan</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>301573391</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:41.920Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106678</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Reloxan</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>301573373</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:41.890Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106685</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Reloxan</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>301574308</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:41.851Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106692</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Reloxan</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>301574391</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:41.811Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106708</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Reloxan</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>301574373</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:41.795Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106715</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Reloxan</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>316571308</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:41.767Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106722</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Reloxan</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>316571391</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:41.740Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106739</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Reloxan</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>316571373</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:41.718Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106746</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Reloxan</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>304572308</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:41.702Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106753</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Reloxan</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>304572391</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:41.669Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106760</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Reloxan</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>304572373</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:41.638Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106777</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Reloxan</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>304573308</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:41.602Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106784</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Reloxan</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>304573391</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:41.567Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106791</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Reloxan</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>304573373</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:41.538Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106807</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Reloxan</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>304574308</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:41.496Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106814</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Reloxan</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>304574391</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:41.434Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106821</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Reloxan</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>304574373</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:41.291Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106838</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Reloxan</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>317571308</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:41.250Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106845</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Reloxan</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>317571391</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:41.205Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106852</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Reloxan</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>317571373</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:41.153Z</lastUpdated>
  </row>
</eudamedExport>